Jichuan Pharmaceutical: Main product Pediatric Chiqiao Qingre Granules newly included in the National Essential Medicine List

Blue Whale News on July 9th: Jichuan Pharmaceutical announced that its wholly-owned subsidiary Jichuan Pharmaceutical Group Co., Ltd.'s main product, Children's Chiqiao Qingre Granules, has been newly included in the "National Essential Medicine List." This product is an exclusive variety, with sales revenue of 1.519 billion yuan in 2025, accounting for 24.43% of the company's revenue; sales revenue in the first quarter of 2026 was 264 million yuan, accounting for 21.87% of revenue. The inclusion will be beneficial for the expansion of the product in the grassroots medical market but will not have a significant impact on the current operating performance.